Affymetrix Makes $62.5M in Payments for Oxford Gene Technologies Royalties | GenomeWeb

Affymetrix on Monday said it would make a one-time payment of $42 million to Oxford Gene Technology, the UK-based firm that manages the intellect-ual property developed by microarray pioneer Edwin Southern of Oxford University.

Additionally, approximately $20.5 million in royalty payments held up by Affymetrix will be released to fully pay any obligations on its license to OGT’s patents for the life of the patents, which is regarded as 10 years, according to the Form 8-K filing with the US Securities and Exchange Commission.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.